首页>投融资
Oxular
收并购
Oxular is developing disruptive technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Oxular's sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye.In March 2021, Oxular Limited announced that it had completed a $37 million financing led by Forbion
基本信息
-
公司全称Oxular Ltd
-
类型视网膜疾病治疗用药物及器械研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址1 Robert Robinson Avenue OXFORD OXFORDSHIRE OX4; GB; Telephone: +441865636200;
-
联系电话(0)1865636200
-
邮箱enquiries@oxular.com
-
成立时间2014-01-01
投融资
-
2025-01-01收并购未透露Regeneron
-
2021-03-01未公开3700万美元Forbion Capital PartnersIP Group PlcNeomed ManagementV-BIO Ventures
-
2016-07-19A轮2060万美元Neomed ManagementConsort MedicalV-BIO Ventures
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息